Exencial Wealth Advisors LLC Invests $4.12 Million in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Exencial Wealth Advisors LLC acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 12,533 shares of the medical research company’s stock, valued at approximately $4,117,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Bio-Rad Laboratories by 1.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock valued at $147,583,000 after purchasing an additional 4,260 shares during the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of Bio-Rad Laboratories by 3.9% in the 3rd quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company’s stock valued at $84,571,000 after purchasing an additional 9,584 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at about $83,681,000. Mawer Investment Management Ltd. lifted its holdings in shares of Bio-Rad Laboratories by 63.0% in the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after purchasing an additional 84,237 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Bio-Rad Laboratories by 4.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 191,867 shares of the medical research company’s stock valued at $63,030,000 after purchasing an additional 7,552 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on BIO. Wells Fargo & Company reduced their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Stock Performance

Shares of BIO stock opened at $251.16 on Wednesday. The company has a market cap of $7.04 billion, a price-to-earnings ratio of -3.86 and a beta of 0.90. The stock has a 50 day simple moving average of $323.99 and a 200-day simple moving average of $331.64. Bio-Rad Laboratories, Inc. has a 12-month low of $248.22 and a 12-month high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.